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Apolipoprotein B is Highly Associated with the Risk of Coronary 
Heart Disease as Estimated by the Framingham Risk Score in 
Healthy Korean Men
The aim of this study was to examine the association between serum apolipoprotein B 
(apoB) and the risk of coronary heart disease (CHD) using Framingham risk score (FRS) in 
healthy Korean men. A total of 13,523 men without medication history of diabetes and 
hypertension were enrolled in this study. The FRS is based on six coronary risk factors. FRS 
≥ 10% was defined as more-than-a-moderate risk group and FRS ≥ 20% as high risk 
group, respectively. The logistic regression analyses were conducted. When quartile 1 (Q1) 
set as a reference, in unadjusted analyses, the Q2, Q3, Q4 of apoB level had increased odds 
ratio (OR) for the risk of CHD in both more-than-a-moderate risk and high risk group, 
respectively. After adjusting for confounding variables, multivariable-adjusted logistic 
regression analyses showed a strong relationship between the quartiles of apoB level and 
more-than-a-moderate risk and high risk group, respectively. These associations were 
attenuated, but still remained statistically significant. ApoB is found to be independently 
related to the risk of CHD using FRS in healthy Korean men, and the link between apoB 
and the risk of CHD is dose-depedent.
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INTRODUCTION
Apolipoproteins (Apo) are the protein components of plasma 
lipoproteins and also known to determine the structural stability 
and metabolism of lipoproteins. ApoB and apoA-I are the main 
structural proteins of low-density lipoprotein (LDL) and high-
density lipoprotein (HDL) particles, respectively. ApoB puts to-
gether the precursors of LDL and very-low-density lipoprotein 
(VLDL) in the liver (1). 
  Until now, diabetes mellitus, hypertension, and dyslipidemia 
have been regarded as established predictors of cardiovascular 
disease. Life style risk factors, including dietary habits, physical 
inactivity, smoking, alcohol intake, stress and obesity strongly 
affect the established cardiovascular risk factors (2-4). The re-
duction of risk factors for cardiovascular disease can prevent 
the incidence of the cardiovascular diseases (5). The assessment, 
treatment, monitoring and prevention of these risk factors are 
major emphases of clinical care, research investigation and treat-
ment guidelines. The Framingham risk prediction model was 
based on the 12 yr of follow-up of 5,573 members of the Fram-
ingham Heart Study, aged 35-74 yr free from symptomatic car-
diovascular diseases at baseline (6). The Framingham risk score 
(FRS) has been a traditionally used algorithm in primary pre-
vention strategies for the assessment of 10-yr risk for coronary 
heart disease (CHD) events in middle-aged, asymptomatic in-
dividuals (7). Recently, several studies have reported that other 
risk factors for CHD were associated with the FRS (8-10).
  However, there have been few reports on the relationship be-
tween apoB and risk of CHD using FRS. Furthermore, no reli-
able data obtained by healthy men without diabetic and hyper-
tensive medication are available regarding the risk of CHD de-
velopment with apoB level. Therefore, we conducted the large 
scaled cross-sectional study. The aim of this study was to deter-
mine whether plasma concentrations of apoB have an elevated 
10-yr risk of developing CHD using FRS in healthy Korean men. 
MATERIALS AND METHODS
Study subjects 
A cross-sectional study was conducted to examine the associa-
tion between serum apoB and risk for CHD in healthy Korean 
men who were employed at various companies in Korea. All em-
ployees participated in an annual health examination, as was 
required by Korea’s Industrial Safety and Health law. A total of 
25,594 men participated in the comprehensive health examina-
tions at a university hospital in Seoul, from January to Decem-Ryoo J-H, et al.  •  Apolipoprotein B and Framingham Risk Score
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ber in 2007. Among them, 3,828 were excluded for various rea-
sons: 14 had a past history of a malignancy; 2,375 were taking 
medication for diabetes; 1,688 were taking medication for hy-
pertension at their initial examinations. Because some individ-
uals had more than one exclusion criterion, the total number 
that was eligible for the study was 21,766. We excluded an addi-
tional 1,075 from our study subjects not calculating FRS, 7,087 
not possessing information about apoB variables and 81 aged 
less than 30 yr old. FRS should be applied to individuals who 
are over 30 yr old (2), because FRS may less accurately predict 
the risk of CHD in younger individuals. Ultimately, 13,523 men, 
aged 30 to 77 yr old, were enrolled in the analysis and were ob-
served the relationship between apoB and the risk of CHD us-
ing FRS. 
Clinical and laboratory measurements 
The initial health examinations that were performed in 2007 in-
cluded a medical history, a physical examination, a question-
naire about health-related behavior, anthropometric measure-
ments, and biochemical measurements. The medical history 
and the history of drug prescription were assessed by the exam-
ining physicians. All the participants were asked to respond to a 
questionnaire on health-related behavior. Questions about al-
cohol intake included the frequency of alcohol consumption 
on a weekly basis and the usual amount that was consumed on 
a daily basis (≥ 20 g/day). We considered persons reporting that 
they smoked at that time to be current smokers. Overweight and 
obesity was defined as a body mass index (BMI) ≥ 25 kg/m
2 for 
all subjects as an index of obesity because this cut-off has been 
proposed for the diagnosis of obesity in Asian people (11).
  Blood samples were collected after more than 12 hr of fasting 
and were drawn from an antecubital vein. The total cholesterol, 
triglycerides, LDL-cholesterol, HDL-cholesterol, alanine ami-
notransferase (ALT) and aspartate aminotransferase (AST) were 
measured enzymatically with an automatic analyzer (Advia 1650 
Autoanalyzer, Bayer Diagnostics; Leverkusen, Germany). The 
fasting serum glucose was measured with the hexokinase meth-
od. Insulin levels were measured with immunoradiometric as-
says (Biosource, N. velles, Belgium). Insulin resistance was as-
sessed with the Homeostasis Model Assessment of insulin re-
sistance (HOMA-IR): Fasting serum insulin (μU/mL) × fasting 
blood glucose (mg/dL)/22.5. High sensitivity-C reactive protein 
(hsCRP) was measured by immunonephelometry (Dade Beh-
ring Co., Marburg, Germany), and apoA-I and apoB measured 
by rate nephelometry (Beckman Instruments, Fullerton, CA, 
USA). Distribution of values was assessed by the Kolmogorov-
Smirnov test for normality of distribution. Because the values of 
hsCRP were skewed to the right, its log-transformed data were 
used in analysis. Train
 ed nurses obtained sitting blood pressure 
(BP) levels with a standard mercury sphygmomanometer. The 
first and fifth Korotkoff sounds were utilized in order to estimate 
the systolic BP and the diastolic BP. Height and weight were mea-
sured after an overnight fast with the subjects wearing a light-
weight hospital gown and no shoes. The BMI was calculated as 
the weight (kg) divided by the square of the height (m). 
Framingham risk score assessment 
The FRS was calculated from the National Cholesterol Educa-
tion Program (NCEP) Adult Treatment Panel (ATP) III algorithm, 
based on six coronary risk factors: gender, age, total cholesterol, 
HDL-cholesterol, systolic BP and smoking habit (7). Among 
these factors, age, BP, and cholesterol levels were categorized 
according to their values and smoking status was classified as 
either “current smoker” or “non-smoker” . Finally, the correspond-
ing point was given to each man and then the total score was 
used as the individual’s CHD risk level. The FRS has been used 
to predict the 10-yr risk of coronary events (fatal/nonfatal myo-
cardial infarction or sudden death) (12). The FRS for CHD over 
10 yr was calculated for each man (12), and divided into three 
levels of risk < 10% (low), 10%-19% (intermediate) and ≥ 20% 
(high) (7). In this study, we defined FRS ≥ 10% as more-than-a-
moderate CHD risk group and FRS ≥ 20% as a high CHD risk 
group, respectively.
Statistical analyses 
The one-way ANOVA and chi-squared test were used to analyze 
the statistical differences across the characteristics of the study 
participants in relation to the quartiles of apoB level and 10 yr-
predicted-risk groups of the FRS. More-than-a-moderate risk 
(FRS ≥ 10%) and high risk (FRS ≥ 20%) were considered as de-
pendent variable. The logistic regression analyses were con-
ducted to calculate the odds ratio (OR) and 95% confidence in-
terval (CI). The data were first unadjusted, then adjusted for the 
multiple covariates. In multivariable model, we included apoB/
apoA-I, BMI, diastolic BP, LDL-cholesterol, triglyceride, ALT, 
HOMA-IR, log (hsCRP) and alcohol intake. The statistical anal-
ysis for the data was performed with SAS version 9.1 (SAS Insti-
tute Inc., Cary, NC, USA). All the reported P values were two-
tailed, and those < 0.05 were considered to be statistically sig-
nificant.
Ethics statement 
This study was approved by the institutional review board of 
Kangbuk Samsung Hospital, Sungkyunkwan University, School 
of Medicine in Seoul, Korea (IRB number: KBC09100). All par-
ticipants gave their written informed consent. 
RESULTS
The relevant clinical characteristics of the 13,523 male subjects 
are shown in Table 1. Overall, the mean ± standard deviation of 
age and FRS were 41.7 ± 7.0 yr and 5.4 ± 5.3, respectively. The Ryoo J-H, et al.  •  Apolipoprotein B and Framingham Risk Score
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mean apoB, apoA-I and apoB/apoA-I were 97.4 ± 20.6 mg/dL, 
135.1 ± 17.9 mg/dL and 0.7 ± 0.2, respectively (mean ± standard 
deviation). The prevalence of current smoker was 25.7%. 37.8% 
of the study subjects had an alcohol intake ≥ 20 g/day. The rele-
vant clinical characteristics in relation to the quartiles (Q) of apoB 
level are shown in Table 2. In the categorical analyses, the FRS 
increased with the quartiles of apoB level (P for trend < 0.001). 
The relevant clinical characteristics in relation to the 10 yr-pre-
dicted-risk groups of FRS are shown in Table 3. These data showed 
that there was a significant relationship between all the clinical 
variables and three groups of the 10 yr-predicted-risk of FRS ex-
cept for BMI. Table 4 presents the OR and 95% CI of the risk of 
CHD with respect to the continuous variable of apoB and the 
quartiles of apoB level. The unadjusted OR and 95% CI of the risk 
of CHD with respect to the continuous variable of apoB was 1.99 
(1.88-2.10) in more-than-a-moderate risk (FRS ≥ 10%) and 4.59 
(3.61-5.84) in high risk (FRS ≥ 20%), respectively. When Q1 set 
as a reference, in unadjusted analyses, the Q2, Q3, Q4 of apoB 
level had increased OR for the risk of CHD in both more-than-
a-moderate risk and high risk group (P for trend < 0.001). After 
adjusting for apoB/apoA-I, BMI, diastolic BP, LDL-cholesterol, 
triglyceride, ALT, HOMA-IR, log (hsCRP) and alcohol intake, mul-
tivariable-adjusted logistic regression analyses showed a strong 
relationship between the quartiles of apoB level and more-than-
a-moderate risk and high risk group, these associations were 
attenuated, but still remained statistically significant. 
  The total of study subjects is 21,766; 13,523 included in analy-
sis and 8,243 excluded from analysis. There are no major incon-
Table 1. Characteristics of the study subjects (n = 13,523)
Age (yr, SD)
   < 40, No. (%)
   40-50, No. (%)
   > 50, No. (%)
41.7 ± (7.0)
  5,617 (41.5)
  6,123 (45.3)
  1,783 (13.2)
BMI (kg/m
2, SD) 24.4 ± (2.7)
Overweight and obesity, No. (%)   5,254 (38.8)
Systolic BP (mmHg, SD) 117.4 ± (14.0)
Diastolic BP (mmHg, SD) 77.2 ± (9.1)
Total cholesterol (mg/dL, SD) 193.5 ± (32.4)
Triglyceride (mg/dL, interquartile range) 123.0 (87.0-174.0)
HDL-cholesterol (mg/dL, SD) 47.3 ± (9.8)
LDL-cholesterol (mg/dL, SD) 117.7 ± (29.4)
ApoB (mg/dL, SD)   97.4 ± (20.6)
ApoA-I (mg/dL, SD) 135.1 ± (17.9)
ApoB/ApoA-I (SD)   0.7 ± (0.2)
AST (IU/L, interquartile range) 23.0 (20.0-28.0)
ALT (IU/L, interquartile range) 24.0 (18.0-34.0)
Fasting serum glucose (mg/dL, SD)   97.3 ± (16.4)
HOMA-IR (interquartile range) 2.2 (1.8-2.7)
Log (hsCRP) (SD) -2.8 ± (1.0)
FRS (SD)
   Low risk (< 10%), No. (%)
   Intermediate risk (10%-19%), No. (%)
   High risk (≥ 20%), No. (%)  
  5.4 ± (5.3)
11,958 (88.4)
  1,360 (10.1)
   205 (1.5)
Current smoker, No. (%)   3,468 (25.7)
Alcohol intake, No. (%)   5,107 (37.8)
All values are the mean ± SD, median (interquartile range) or the number of subjects 
(percent of the total). SD, standard deviation; BMI, body mass index; BP, blood pres-
sure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HOMA-IR, 
Homeostasis Model Assessment of insulin resistance; hsCRP, high-sensitivity C-reactive 
protein; FRS, Framingham risk score.
Table 2. Comparison of baseline characteristics among quartile groups of ApoB level (n = 13,523)
Variables
ApoB (mg/dL)
P for trend*  Q1 (< 83.18)  
n = 3,378
Q2 (≥ 83.18, < 96.06)  
n = 3,383
Q3 (≥ 96.06, < 110.26)  
n = 3,381
Q4 (≥ 110.26)  
n = 3,381
Age (yr, SD) 40.4 ± (7.1) 41.5 ± (7.1) 42.2 ± (6.9) 42.8 ± (6.8) < 0.001
BMI (kg/m
2, SD) 24.3 ± (2.7) 24.3 ± (2.7) 24.4 ± (2.7) 24.4 ± (2.8) 0.112
Systolic BP (mmHg, SD) 117.0 ± (13.9) 117.5 ± (14.2) 117.6 ± (14.1) 117.5 ± (14.0) 0.180
Diastolic BP (mmHg, SD) 77.0 ± (8.8) 77.1 ± (9.0) 77.4 ± (9.3) 77.2 ± (9.1) 0.182
Total cholesterol (mg/dL, SD) 160.1 ± (19.3) 182.8 ± (17.0) 200.6 ± (16.9) 230.2 ± (25.1) < 0.001
Triglyceride (mg/dL, SD) 109.5 ± (76.3) 133.1 ± (81.5) 152.0 ± (84.3) 179.7 ± (90.0) < 0.001
HDL-cholesterol (mg/dL, SD) 50.0 ± (11.5) 47.2 ± (9.8) 46.4 ± (9.0) 45.7 ± (8.0) < 0.001
LDL-cholesterol (mg/dL, SD) 86.5 ± (16.4) 109.2 ± (14.6) 125.0 ± (16.5) 150.0 ± (24.0) < 0.001
ApoA-I (mg/dL, SD) 136.1 ± (19.3) 134.2 ± (17.9) 134.4 ± (17.4) 135.6 ± (17.0) 0.336
ApoB/ApoA-I (SD) 0.5 ± (0.1) 0.7 ± (0.1) 0.8 ± (0.1) 0.9 ± (0.1) < 0.001
AST (IU/L, SD) 23.4 ± (8.3) 24.3 ± (7.9) 25.3 ± (9.1) 27.0 ± (10.4) < 0.001
ALT (IU/L, SD) 24.3 ± (13.9) 27.3 ± (15.5) 30.2 ± (16.8) 34.5 ± (19.8) < 0.001
Fasting serum glucose (mg/dL, SD) 95.3 ± (13.9) 96.4 ± (14.0) 97.4 ± (15.2) 99.9 ± (20.8) < 0.001
HOMA-IR (SD) 2.3 ± (0.9) 2.4 ± (1.0) 2.4 ± (0.9) 2.4 ± (0.9) < 0.001
Log (hsCRP) (SD) -3.0 ± (1.0) -2.9 ± (1.0) -2.8 ± (1.0) -2.6 ± (0.9) < 0.001
FRS (SD)
   Low risk (< 10%), No. (%)
   Intermediate risk (10%-19%), No. (%)
   High risk (≥ 20%), No. (%)
2.1 ± (5.6)
3,285 (97.3)
92 (2.7)
1 (0.0)
4.8 ± (4.9)
3,121 (92.3)
251 (7.4)
11 (0.3)
6.3 ± (4.6)
2,908 (86.0)
441 (13.1)
32 (0.9)
8.1 ± (4.2)
2,644 (78.2)
576 (17.0)
161 (4.8)
< 0.001
< 0.001
Current smoker, No. (%) 838 (24.8) 874 (25.8) 868 (25.7) 888 (26.3) 0.210
Alcohol intake, No. (%) 1,272 (37.7) 1,282 (37.9) 1,259 (37.3) 1,294 (38.3) 0.737
Categorical data presented as No. (%); continuous data presented as mean (SD). *P value by ANOVA for continuous variables and chi square test for categorical variables.Ryoo J-H, et al.  •  Apolipoprotein B and Framingham Risk Score
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sistencies between the exclusion and inclusion of individuals 
except for age, fasting serum glucose and alcohol intake. There-
fore, exclusion of these individuals would be unlikely to cause 
bias (data not shown).
DISCUSSION
This study demonstrated that apoB showed significant relation-
ship with three groups of the 10 yr-predicted-risk of FRS. In un-
adjusted and multivariable-adjusted logistic regression analy-
ses, apoB was found to be independently related to the risk of 
CHD using FRS in healthy Korean men, and the link between 
apoB and the risk of CHD was found to be dose-response relat-
ed. In addition, apoB with a high risk showed a tendency to in-
crease the risk of developing CHD. These findings provided an 
important point of view understanding the incidence of CHD, 
and furthermore, supported the notion that apoB should be 
considered as an additional atherogenic parameter in relation 
to CHD. As far as we know, few epidemiologic studies have ex-
plored the link between apoB and the risk of CHD using FRS, 
especially healthy men. Our findings are so valuable for the basis 
of the public health because these are based on a large sample 
of the general population of Korean men, where the incidence 
of CHD is common. 
Table 3. Characteristics of the study subjects stratified for 10-yr predicted risk groups (n = 13,523)
Variables
10-yr predicted risk groups of FRS 
P for trend*
Low (n = 11,958) Intermediate (n = 1,360) High (n = 205)
Age (yr, SD) 40.8 ± (6.4) 48.5 ± (7.9) 49.0 ± (6.9) < 0.001
BMI (kg/m
2, SD) 24.4 ± (2.7) 24.4 ± (2.7) 24.5 ± (2.9) 0.405
Systolic BP (mmHg, SD) 117.2 ± (13.9) 118.4 ± (14.7) 122.7 ± (16.0) < 0.001
Diastolic BP (mmHg, SD) 77.1 ± (9.0) 77.7 ± (9.6) 79.3 ± (10.0) < 0.001
Total cholesterol (mg/dL, SD) 191.1 ± (31.7) 208.6 ± (31.3) 231.5 ± (30.7) < 0.001
Triglyceride (mg/dL, SD) 140.6 ± (85.4) 160.5 ± (89.6) 208.5 ± (120.1) < 0.001
HDL-cholesterol (mg/dL, SD) 47.6 ± (9.9) 45.4 ± (8.5) 42.2 ± (6.4) < 0.001
LDL-cholesterol (mg/dL, SD) 115.7 ± (28.9) 131.0 ± (28.4) 147.1 ± (31.5) < 0.001
ApoB (mg/dL, SD) 95.6 ± (20.2) 108.7 ± (18.7) 123.2 ± (16.8) < 0.001
ApoA-I (mg/dL, SD) 135.4 ± (18.1) 133.4 ± (17.0) 128.9 ± (14.4) < 0.001
ApoB/ApoA-I (SD) 0.7 ± (0.2) 0.8 ± (0.2) 1.0 ± (0.1) < 0.001
AST (IU/L, SD) 24.9 ± (9.0) 26.1 ± (9.2) 26.7 ± (12.5) 0.005
ALT (IU/L, SD) 28.8 ± (17.0) 30.7 ± (17.2) 31.8 ± (16.6) 0.015
Fasting serum glucose (mg/dL, SD) 96.7 ± (15.5) 101.2 ± (20.8) 102.9 ± (28.0) < 0.001
HOMA-IR (SD) 2.4 ± (0.9) 2.5 ± (0.9) 2.5 ± (1.1) 0.020
Log (hsCRP) (SD) -2.8 ± (1.0) -2.7 ± (0.9) -2.6 ± (1.0) 0.001
Current smoker, No. (%) 2,177 (18.2) 1,089 (80.1) 202 (98.5) < 0.001
Alcohol intake, No. (%) 4,195 (35.1) 774 (56.9) 138 (67.3) < 0.001
Categorical data presented as No. (%); continuous data presented as mean (SD). *P value by ANOVA for continuous variables and chi square test for categorical variables.
Table 4. Odds ratio (OR) and 95% confidence intervals (CI) assessing the independent influence of ApoB on more-than-a-moderate risk (FRS ≥ 10%) and high risk (FRS ≥ 20%) 
of CHD 
Variables 
FRS ≥ 10% (vs < 10%) FRS ≥ 20% (vs < 20%)
Unadjusted Multivariate-adjusted* Unadjusted Multivariate-adjusted*
ApoB 
   Q1 (< 83.18)
   Q2 (≥ 83.18, < 96.06)
   Q3 (≥ 96.06, < 110.26)
   Q4 (≥ 110.26)
   P for linear trend
 
1.00 (reference)
 2.97 (2.33-3.78)
 5.75 (4.57-7.21)
   9.85 (7.89-12.29)
< 0.001
 
1.00 (reference)
 2.16 (1.67-2.79)
 3.38 (2.59-4.40)
 4.01 (2.92-5.52)
< 0.001
 
1.00 (reference)
  11.02 (1.42-85.37)
    32.27 (4.41-236.27)
    168.85 (23.63-999.99)
< 0.001
 
1.00 (reference)
   6.14 (0.79-47.87)
 12.03 (1.62-89.47)
   31.05 (4.13-233.58)
< 0.001
ApoB (continuous variable)   1.99 (1.88-2.10)   4.59 (3.61-5.84)
ApoB/ApoA-I    43.18 (32.07-58.15)    6.90 (4.18-11.37)       358.55 (181.80-707.15)  28.14 (9.42-84.06)
BMI  1.01 (0.99-1.03)  0.99 (0.97-1.01)   1.02 (0.97-1.07)  0.99 (0.94-1.05)
Diastolic BP  1.01 (1.01-1.02)  1.01 (1.01-1.02)   1.03 (1.01-1.04)  1.02 (1.01-1.04)
LDL-cholesterol  1.02 (1.01-1.02)  1.00 (1.00-1.01)   1.03 (1.02-1.03)  1.01 (1.00-1.01)
Triglyceride  1.01 (1.01-1.02)  1.00 (1.00-1.00)   1.01 (1.00-1.01)  1.01 (1.00-1.01)
ALT  1.01 (1.01-1.02)  1.00 (1.00-1.01)   1.00 (1.00-1.01)  0.99 (0.98-1.00)
HOMA-IR  1.12 (1.06-1.18)  1.09 (1.03-1.15)   1.12 (1.01-1.24)  1.06 (0.93-1.22)
Log (hsCRP)  1.15 (1.10-1.21)  1.02 (0.96-1.08)   1.22 (1.08-1.38)  0.97 (0.83-1.13)
Alcohol intake  2.59 (2.32-2.88)  2.77 (2.48-3.10)   3.46 (2.58-4.64)  3.69 (2.73-5.00)
*Multivariate-adjusted for apoB/apoA-I, BMI, diastolic BP, LDL-cholesterol, triglyceride, ALT, HOMA-IR, log (hsCRP) and alcohol intake.Ryoo J-H, et al.  •  Apolipoprotein B and Framingham Risk Score
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  In the western countries, high apoB and low apoA-I have been 
shown to be an independent predictor of CHD (13-18); however, 
there have been no evidence to date that apos have a predictive 
value for CHD in Korea, even in Asian countries. In this regard, 
the present findings suggest the possibility that apoB rather than 
other atherogenic parameter, such as LDL-cholesterol, triglyc-
eride and alcohol intake might be able to predict the future de-
velopment of CHD in Korean population. 
  The mechanisms and the reasons that the apoB is highly as-
sociated with the CHD are not fully understood. However, Snider-
man et al. (19) emphasized the importance of apoB in the de-
velopment of cardiovascular disease, suggesting that the risk of 
cardiovascular disease is maximized if hypertriglyceridemia was 
associated with the high level of apoB, as an increased number 
of LDL particles and density. 
  Several recent reports have presented the possibility that the 
apos have been proposed as a better index for predicting the 
risk of cardiovascular disease than the traditional lipid parame-
ters, based on the premise that apoB levels fully reflect the num-
ber of atherogenic lipoprotein particles, such as VLDL, interme-
diate-density lipoproteins, and LDL (13, 14, 18, 20-23). In the 
present study, the odds ratio of apoB was bigger than that of oth-
er lipid parameters. 
  The findings of the present study have clinically important 
implications. ApoB measurements may be more convenient, 
because they do not require blood sampling at fasting status (24). 
The costs for apoB measurement are lower than those of total 
cholesterol and HDL-cholesterol (25). The present diagnostic 
guideline of dyslipidemia did not include the apoB level in clin-
ical settings, and the proper guideline for diagnose, treatment 
and medication should also be established, sooner or later.
  This study has several potential limitations. First, this study is 
just confined to relatively racially homogeneous male of indi-
viduals of Korean ancestry who were recruited at a single urban 
hospital, so we cannot extrapolate our results to another race. 
Second, we used the FRS scales which were applied for the west-
ern people, so the FRS in this study may not reflect the typical 
characteristics of Korean people completely. In the future, FRS 
scales for Korean people should be prepared for next analysis. 
Despite these limitations, strengths of the present study include 
the large number of healthy male participants with comprehen-
sive measurement of a panel of lipids and apos, including the 
direct measurement of lipids. Additionally, detailed informa-
tion on cardiovascular risk factors was available. The partici-
pants not only had no past histories of a malignancy but also 
did not take medication for diabetes and hypertension at their 
initial examinations. So, this study was considered to provide 
strong evidence for association between FRS and the other var-
ious lipid parameters, such as apoB, apoA-I and so on. 
  In conclusion, our results strongly suggest that apoB is inde-
pendently related to the risk of CHD using FRS in healthy Korean 
men, and the link between apoB and the risk of CHD is found 
to be dose-dependent. 
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AUTHOR SUMMARY
Apolipoprotein B is Highly Associated with the Risk of Coronary Heart Disease as 
Estimated by the Framingham Risk Score in Healthy Korean Men
Jae-Hong Ryoo, Eun- Hee Ha, Soo-Geun Kim, Seungho Ryu, and Da-Woon Lee
Apolipoproteins (Apos) are the protein components of plasma lipoproteins. In the western countries, high apoB has been shown to 
be an independent predictor of coronary heart disease (CHD); however, there is no evidence to date that apoB has a predictive 
value for CHD in Korea. Here we investigated whether the plasma concentrations of apoB have an elevated 10-yr risk of 
developing CHD using Framingham risk score (FRS) in healthy Korean men. Multivariable-adjusted logistic regression analyses 
showed a strong relationship between the quartile groups of apoB and high CHD risk group. ApoB measurement is more 
convenient, because it does not require fasting status. Therefore, our data suggest that apoB could be considered as an additional 
predictive parameter in relation to the CHD.